The time, venue, and agenda of the 2022 annual
general meeting.
Date of events
2022/03/21
To which item it meets
paragraph 17
Statement
1.Date of the board of directors' resolution:2022/03/21
2.Shareholders meeting date:2022/06/17
3.Shareholders meeting location:CHANG YUNG-FA FOUNDATION International
Convention Center, 10F, No.11, Zhongshan S. Rd., Taipei City 10048,
Taiwan (R.O.C.)
4.Shareholders meeting will be held by means of (physical shareholders
meeting/ visual communication assisted shareholders meeting /
visual communication shareholders meeting):physical shareholders meeting
5.Cause for convening the meeting (1)Reported matters:
(1)2021 Business Reports.
(2)Audit Committee!&s review of the Annual Financial Audit Report of
Year 2021.
(3)For the 2021 Financial Report and the execution status of Sound
Business Plan.
6.Cause for convening the meeting (2)Acknowledged matters:
(1)To accept 2021 Business Report and Consolidated Financial Report.
(2)To accept proposal of 2021 loss make-up.
7.Cause for convening the meeting (3)Matters for Discussion:
(1)To amend the Operational Procedures for Acquisition and Disposal of
Assets.
(2)To amend the Company!&s Memorandum and Articles of Association.
8.Cause for convening the meeting (4)Election matters:
Re-election of Board of Directors.
9.Cause for convening the meeting (5)Other Proposals:
Proposal for release the prohibition on Directors from participation in
competitive business.Proposal for release the prohibition on Directors from
participation in competitive business.
10.Cause for convening the meeting (6)Extemporary Motions:None
11.Book closure starting date:2022/04/19
12.Book closure ending date:2022/06/17
13.Any other matters that need to be specified:
(1)According to Article 52 of the Company!&s Memorandum
and Articles of Association, shareholder(s) holding one
percent (1%) or more of the total number of outstanding
shares of the Company may propose to the Company one
proposal in writing for discussion at the annual general
meeting from 9 am to 5 pm, April 1, 2022 to April 11, 2022.
Acceptance Office: TANVEX BIOPHARMA, INC.(13F.-1, No.376,
Sec. 4, Ren!&ai Rd., Da!&an Dist.,Taipei City).
(2)For those who intends to propose a list of candidates
for independent directors, the company plans to accept
such list of candidates for independent directors daily
from 9 am to 5 pm, April 1, 2022 to April 11, 2022
(the proposals from those who serve its proposal by mail
should be sent via registered mail and should arrive at
the acceptance office by the deadline fixed for
accepting such candidates list; in such circumstance
the words !'letter for nomination of candidates for
independent directors!(should be put on the envelope to
be sent by mail and contact person and contact information
should be stated).
(3)The voting power at this shareholders' meeting
may be exercised via electronic transmission
with reference to Article 177-1 of the Company Act
of R.O.C. The method for exercising the voting power
via electronic transmission will be described in
the shareholders' meeting notice and be compliant
with applicable laws.
Attachments
Original Link
Original Document
Permalink
Disclaimer
Tanvex Biopharma Inc. published this content on 21 March 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 21 March 2022 11:17:06 UTC.
Tanvex BioPharma, Inc. is a Cayman Islands-based biopharmaceutical company focused on the biosimilar market. The company has expertise in areas, including strain and cell-line development in both microbial and mammalian systems, cell culture, protein purification, process scale-up, drug substance and product manufacturing, and others. The Companyâs product pipeline includes Neupogen (TX-01), Herceptin (TX-05), Neulasta (TX-04), Avastin (TX-16), Perjeta (TX-52), and others. The Company offers a vertically integrated manufacturing platform for biopharmaceuticals. The Company is developing and delivering biologic and biosimilar drugs to people.
TANVEX BIOPHARMA, INC. 
